CY1125360T1 - Αγωνιστες 5ητ για τη θεραπεια διαταραχων επιληψιας - Google Patents
Αγωνιστες 5ητ για τη θεραπεια διαταραχων επιληψιαςInfo
- Publication number
- CY1125360T1 CY1125360T1 CY20221100428T CY221100428T CY1125360T1 CY 1125360 T1 CY1125360 T1 CY 1125360T1 CY 20221100428 T CY20221100428 T CY 20221100428T CY 221100428 T CY221100428 T CY 221100428T CY 1125360 T1 CY1125360 T1 CY 1125360T1
- Authority
- CY
- Cyprus
- Prior art keywords
- agonists
- treatment
- epilepsy disorders
- epilepsy
- disorders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562120726P | 2015-02-25 | 2015-02-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1125360T1 true CY1125360T1 (el) | 2025-05-09 |
Family
ID=56789223
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20221100428T CY1125360T1 (el) | 2015-02-25 | 2022-06-22 | Αγωνιστες 5ητ για τη θεραπεια διαταραχων επιληψιας |
Country Status (21)
| Country | Link |
|---|---|
| US (5) | US10874643B2 (https=) |
| EP (4) | EP4043016B1 (https=) |
| JP (5) | JP6884703B2 (https=) |
| KR (3) | KR20220048045A (https=) |
| CN (2) | CN113546174A (https=) |
| AU (3) | AU2016222804C1 (https=) |
| BR (1) | BR112017018297B1 (https=) |
| CA (2) | CA2977135C (https=) |
| CY (1) | CY1125360T1 (https=) |
| DK (1) | DK3261640T3 (https=) |
| EA (2) | EA201992474A3 (https=) |
| ES (2) | ES2920886T3 (https=) |
| HR (1) | HRP20220822T1 (https=) |
| HU (1) | HUE059559T2 (https=) |
| LT (1) | LT3261640T (https=) |
| PL (1) | PL3261640T3 (https=) |
| PT (1) | PT3261640T (https=) |
| RS (1) | RS63426B1 (https=) |
| SI (1) | SI3261640T1 (https=) |
| SM (1) | SMT202200276T1 (https=) |
| WO (1) | WO2016138138A1 (https=) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9549909B2 (en) | 2013-05-03 | 2017-01-24 | The Katholieke Universiteit Leuven | Method for the treatment of dravet syndrome |
| CN113546174A (zh) | 2015-02-25 | 2021-10-26 | 加利福尼亚大学董事会 | 用于治疗病症的5ht激动剂 |
| GB201620095D0 (en) * | 2016-11-28 | 2017-01-11 | Terali Innov Sas And Univ De Strasbourg And Inserm (Inst Nat De La Sante Et De La Rech Medicale) And | Novel use |
| WO2017112701A1 (en) | 2015-12-22 | 2017-06-29 | Zogenix International Limited | Metabolism resistant fenfluramine analogs and methods of using the same |
| PT4293009T (pt) | 2015-12-22 | 2025-09-08 | Zogenix International Ltd | Composições de fenfluramina e métodos de preparação das mesmas |
| AU2017315273B2 (en) | 2016-08-24 | 2021-04-29 | Zogenix International Limited | Formulation for inhibiting formation of 5-HT 2B agonists and methods of using same |
| WO2018115010A1 (en) | 2016-12-20 | 2018-06-28 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene |
| ES2769286T3 (es) | 2016-12-20 | 2020-06-25 | Lts Lohmann Therapie Systeme Ag | Sistema terapéutico transdérmico que contiene asenapina |
| ES2881783T3 (es) | 2017-06-26 | 2021-11-30 | Lts Lohmann Therapie Systeme Ag | Sistema terapéutico transdérmico que contiene asenapina y polímero de acrílico y silicona |
| US10682317B2 (en) * | 2017-09-26 | 2020-06-16 | Zogenix International Limited | Ketogenic diet compatible fenfluramine formulation |
| EP3790537A1 (en) | 2018-05-11 | 2021-03-17 | Zogenix International Limited | Compositions and methods for treating seizure-induced sudden death |
| EP3806835A1 (en) | 2018-06-14 | 2021-04-21 | Zogenix International Limited | Compositions and methods for treating respiratory depression with fenfluramine |
| CA3101420A1 (en) | 2018-06-20 | 2019-12-26 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing asenapine |
| CN112533593A (zh) | 2018-06-20 | 2021-03-19 | 罗曼治疗系统股份公司 | 含有阿塞那平的透皮治疗系统 |
| US12268683B2 (en) | 2018-07-18 | 2025-04-08 | The Regents Of The University Of California | Compounds and methods for synergistic activation of M channels |
| WO2020023923A1 (en) * | 2018-07-27 | 2020-01-30 | Xenon Pharmaceuticals Inc. | Method for treating epilepsy |
| AU2019384963B2 (en) | 2018-11-19 | 2022-05-26 | Zogenix International Limited | Methods of treating Rett syndrome using fenfluramine |
| EP3976187A4 (en) * | 2019-05-29 | 2023-08-02 | The Regents of the University of California | METHODS AND COMPOSITIONS FOR THE TREATMENT OF EPILEPSY |
| EP3791873A1 (en) | 2019-09-16 | 2021-03-17 | Universite De Bordeaux | Methods of treatment and/or prevention of disorders and symptoms related to bkca and/or sk channelophathies |
| KR20220087507A (ko) * | 2019-10-23 | 2022-06-24 | 뉴로사이클 테라퓨틱스, 인크. | Gabaa 수용체 조절제를 사용한 간질 병태의 치료 |
| FI4048249T3 (fi) * | 2019-10-23 | 2025-12-05 | Maplight Therapeutics Inc | Menetelmiä autismikirjon häiriön oireiden hoitamiseksi |
| KR20210054684A (ko) | 2019-11-06 | 2021-05-14 | 동국대학교 경주캠퍼스 산학협력단 | 라미나린을 유효성분으로 함유하는 허혈성 뇌혈관 질환 예방용 조성물 |
| JP7780431B2 (ja) * | 2019-12-06 | 2025-12-04 | マリナス ファーマシューティカルズ， インコーポレイテッド | 結節性硬化症の治療での使用のためのガナキソロン |
| KR102476771B1 (ko) * | 2020-05-08 | 2022-12-13 | 광운대학교 산학협력단 | 뇌질환 검증용 eeg 바이오 마커 분석 알고리즘을 통하여 소아 뇌전증 환자 미주신경자극술 효과를 예측하는 방법 |
| US11612574B2 (en) | 2020-07-17 | 2023-03-28 | Zogenix International Limited | Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) |
| BR112023019407A2 (pt) * | 2021-03-25 | 2023-11-28 | Maplight Therapeutics Inc | Composições farmacêuticas compreendendo zolmitriptano |
| EP4346804A4 (en) * | 2021-06-01 | 2025-05-07 | Arena Pharmaceuticals, Inc. | TREATMENT PROCEDURES |
| CN117580579A (zh) * | 2021-06-10 | 2024-02-20 | 纽瑞莱斯有限公司 | 用于治疗儿科患者的癫痫发作病症的方法和组合物 |
| CN118043034A (zh) * | 2021-07-30 | 2024-05-14 | 艾匹真尼克斯治疗公司 | 克立咪唑制剂 |
| WO2023107965A1 (en) * | 2021-12-06 | 2023-06-15 | Terran Biosciences, Inc. | Salt and solid forms of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (dom), 2,5-dimethoxy-4-iodoamphetamine (doi), 2,5-dimethoxy-4-bromoamphetamine (dob), and 2,5-dimethoxy-4-chloroamphetamine (doc) |
| US11974992B2 (en) | 2022-01-26 | 2024-05-07 | Neurolixis | Use of serotonin 5-HT1A receptor agonists to treat diseases associated with sudden unexpected death in epilepsy |
| WO2023144166A1 (en) | 2022-01-26 | 2023-08-03 | Neurolixis | Use of serotonin 5-ht1a receptor agonists to treat diseases associated with sudden unexpected death in epilepsy |
| WO2023212244A1 (en) * | 2022-04-27 | 2023-11-02 | Tessellate Therapeutics, Inc. | Methods of treating 5ht2a receptor-mediated conditions |
| CA3247344A1 (en) | 2022-06-09 | 2023-12-14 | Diamond Therapeutics Inc. | AMORPHIC PSILOCYBIN (A-POLYMORPHIC) |
| WO2024118280A1 (en) * | 2022-11-30 | 2024-06-06 | Mind Medicine, Inc. | 4-alkenyl and 4-alkynyl phenethylamine derivatives and related compounds with modified dom-like action |
| CN119564685B (zh) * | 2024-12-16 | 2026-02-06 | 中国人民解放军军事科学院军事医学研究院 | Yl-0919在癫痫或癫痫导致的脑损伤治疗中的应用 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2436883C2 (de) | 1974-07-29 | 1985-08-22 | Schering AG, 1000 Berlin und 4709 Bergkamen | Benzimidazol-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel |
| US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
| FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
| ATE141502T1 (de) | 1991-01-15 | 1996-09-15 | Alcon Lab Inc | Verwendung von karrageenan in topischen ophthalmologischen zusammensetzungen |
| US5212162A (en) | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
| US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| US6323237B1 (en) * | 1997-03-17 | 2001-11-27 | Btg International Limited | Therapeutic compositions |
| GB9927844D0 (en) * | 1999-11-26 | 2000-01-26 | Glaxo Group Ltd | Chemical compounds |
| US7326536B2 (en) | 2001-05-03 | 2008-02-05 | Eli Lilly And Company | Agents for treatment of HCV and methods of use |
| US6559293B1 (en) | 2002-02-15 | 2003-05-06 | Transform Pharmaceuticals, Inc. | Topiramate sodium trihydrate |
| US7582428B2 (en) | 2003-08-22 | 2009-09-01 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for identifying anti-HCV agents |
| US20050215589A1 (en) | 2003-09-03 | 2005-09-29 | Roger Crossley | Inhibitors of 5-HT2A receptor |
| EP1787679A1 (en) * | 2005-07-29 | 2007-05-23 | Laboratorios Del Dr. Esteve, S.A. | Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain |
| US7635710B2 (en) | 2006-02-15 | 2009-12-22 | Neurim Pharmaceuticals (1991) Ltd. | Pyrone-indole derivatives and process for their preparation |
| EP2068872A1 (en) * | 2006-09-08 | 2009-06-17 | Braincells, Inc. | Combinations containing a 4-acylaminopyridine derivative |
| US8642351B2 (en) | 2006-09-20 | 2014-02-04 | Waters Technologies Corporation | Apparatus and methods of fluid chromatography |
| US8402815B2 (en) | 2007-04-06 | 2013-03-26 | Koninklijke Philips Electronics N.V. | Air pollution sensor system |
| TW200848063A (en) * | 2007-04-23 | 2008-12-16 | Combinatorx Inc | Methods and compositions for the treatment of neurodegenerative disorders |
| CA2687715A1 (en) | 2007-05-09 | 2008-11-20 | Traffick Therapeutics Inc. | Screening assay to identify correctors of protein trafficking defects |
| EP2203168B1 (en) | 2007-09-18 | 2014-07-16 | Stanford University | Compositions for treating a flaviviridae family viral infection |
| KR100925176B1 (ko) | 2007-09-21 | 2009-11-05 | 한국전자통신연구원 | 지리 정보를 이용한 네트워크 상태 표시장치 및 방법 |
| BRPI0908098A2 (pt) | 2008-02-19 | 2015-08-18 | Adolor Corp | Beloxepina, composição, métodos para tratar dor em um mamífero, para inibir a recaptação de ne, para antagonizar um receptor de 5ht2 e para tratar um distúrbio em um paciente que é responsivo ao tratamento com um composto nri e com um composto antagonista de 5ht2 |
| CN102066319A (zh) | 2008-04-16 | 2011-05-18 | 艾尼纳制药公司 | 用于合成(r)-1-{2-[4’-(3-甲氧基丙-1-磺酰基)-联苯-4-基]-乙基}-2-甲基-吡咯烷的方法 |
| DK2307035T3 (da) | 2008-05-16 | 2014-01-20 | Nono Inc | Anvendelse af en PSD-95 inhibitor ved behandlingen af epilepsi |
| WO2010039195A2 (en) | 2008-09-23 | 2010-04-08 | The Board Of Trustees Of The Leland Stanford Junior University | Screening for inhibitors of hcv amphipathic helix (ah) function |
| WO2010107739A2 (en) | 2009-03-18 | 2010-09-23 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions of treating a flaviviridae family viral infection |
| EP2408448A4 (en) | 2009-03-18 | 2012-09-19 | Univ Leland Stanford Junior | METHODS AND COMPOSITIONS FOR TREATING INFECTION WITH A FLAVIVIRIDAE FAMILY VIRUS |
| US8772479B2 (en) | 2009-05-13 | 2014-07-08 | Nektar Therapeutics | Oligomer-containing substituted aromatic triazine compounds |
| EP2491033A4 (en) | 2009-10-20 | 2013-03-13 | Eiger Biopharmaceuticals Inc | AZAINDAZOLES FOR THE TREATMENT OF FLAVIVIRIDAE VIRUS INFECTION |
| WO2014123909A1 (en) | 2013-02-05 | 2014-08-14 | University Of Washington Through Its Center For Commercialization | Positive allosteric modulators of the gaba-a receptor in the treatment of autism |
| US9549909B2 (en) * | 2013-05-03 | 2017-01-24 | The Katholieke Universiteit Leuven | Method for the treatment of dravet syndrome |
| DK3035926T3 (da) * | 2013-08-19 | 2020-08-31 | Univ California | Forbindelser og fremgangsmåder til behandling af en epilepsilidelse |
| WO2015066344A1 (en) * | 2013-11-01 | 2015-05-07 | Arena Pharmaceuticals, Inc. | 5-ht2c receptor agonists and compositions and methods of use |
| WO2015096119A1 (zh) * | 2013-12-27 | 2015-07-02 | 杭州普晒医药科技有限公司 | 氯卡色林盐及其晶体、其制备方法和用途 |
| CN113546174A (zh) | 2015-02-25 | 2021-10-26 | 加利福尼亚大学董事会 | 用于治疗病症的5ht激动剂 |
| GB2539472A (en) * | 2015-06-17 | 2016-12-21 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
-
2016
- 2016-02-24 CN CN202111041649.4A patent/CN113546174A/zh active Pending
- 2016-02-24 CA CA2977135A patent/CA2977135C/en active Active
- 2016-02-24 EP EP22157142.5A patent/EP4043016B1/en active Active
- 2016-02-24 PT PT167562826T patent/PT3261640T/pt unknown
- 2016-02-24 DK DK16756282.6T patent/DK3261640T3/da active
- 2016-02-24 SM SM20220276T patent/SMT202200276T1/it unknown
- 2016-02-24 PL PL16756282.6T patent/PL3261640T3/pl unknown
- 2016-02-24 SI SI201631545T patent/SI3261640T1/sl unknown
- 2016-02-24 EA EA201992474A patent/EA201992474A3/ru unknown
- 2016-02-24 HU HUE16756282A patent/HUE059559T2/hu unknown
- 2016-02-24 BR BR112017018297-1A patent/BR112017018297B1/pt active IP Right Grant
- 2016-02-24 LT LTEPPCT/US2016/019368T patent/LT3261640T/lt unknown
- 2016-02-24 EA EA201791882A patent/EA201791882A1/ru unknown
- 2016-02-24 US US15/552,784 patent/US10874643B2/en active Active
- 2016-02-24 KR KR1020227011498A patent/KR20220048045A/ko not_active Ceased
- 2016-02-24 WO PCT/US2016/019368 patent/WO2016138138A1/en not_active Ceased
- 2016-02-24 CA CA3204599A patent/CA3204599A1/en active Pending
- 2016-02-24 RS RS20220598A patent/RS63426B1/sr unknown
- 2016-02-24 EP EP16756282.6A patent/EP3261640B1/en active Active
- 2016-02-24 AU AU2016222804A patent/AU2016222804C1/en active Active
- 2016-02-24 CN CN201680023991.2A patent/CN107530326B/zh active Active
- 2016-02-24 EP EP19211183.9A patent/EP3632434A1/en not_active Withdrawn
- 2016-02-24 HR HRP20220822TT patent/HRP20220822T1/hr unknown
- 2016-02-24 KR KR1020177026528A patent/KR102385665B1/ko active Active
- 2016-02-24 EP EP25211402.0A patent/EP4696377A3/en active Pending
- 2016-02-24 KR KR1020237037303A patent/KR20230152844A/ko active Pending
- 2016-02-24 JP JP2017544887A patent/JP6884703B2/ja active Active
- 2016-02-24 ES ES16756282T patent/ES2920886T3/es active Active
- 2016-02-24 ES ES22157142T patent/ES3060954T3/es active Active
-
2019
- 2019-11-08 US US16/679,112 patent/US11648237B2/en active Active
-
2020
- 2020-05-01 JP JP2020081127A patent/JP2020143087A/ja active Pending
- 2020-10-28 US US17/082,929 patent/US20210154171A1/en active Pending
-
2021
- 2021-06-23 AU AU2021204261A patent/AU2021204261B2/en active Active
- 2021-08-05 JP JP2021128790A patent/JP7846506B2/ja active Active
-
2022
- 2022-05-16 AU AU2022203274A patent/AU2022203274B2/en active Active
- 2022-06-06 JP JP2022091363A patent/JP2022116307A/ja active Pending
- 2022-06-22 CY CY20221100428T patent/CY1125360T1/el unknown
-
2023
- 2023-03-30 US US18/192,955 patent/US12447144B2/en active Active
- 2023-09-29 JP JP2023169390A patent/JP2024009839A/ja active Pending
-
2025
- 2025-05-29 US US19/222,750 patent/US20260083706A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1125360T1 (el) | Αγωνιστες 5ητ για τη θεραπεια διαταραχων επιληψιας | |
| CY1124293T1 (el) | Αγωνιστης υποδοχεα γλυκοκορτικοειδων και ανοσοσυζευγματα αυτου | |
| PL3660004T3 (pl) | Związki i sposoby do ukierunkowanej degradacji receptora androgenowego | |
| MX380810B (es) | Sondas para la proyección de imagen de la proteína huntingtina. | |
| MX2017006320A (es) | Terapia combinada que comprende agonistas de unión de ox40 y antagonistas de unión del eje de pd-1. | |
| BR112018001853A2 (pt) | métodos para tratamento de um distúrbio e para melhoria do tratamento de um distúrbio | |
| EA201791117A1 (ru) | Частичные агонисты инсулинового рецептора | |
| EA201791421A1 (ru) | Антитела против csf1r для лечения pvns | |
| MX372543B (es) | Moduladores de receptor nuclear. | |
| EA201791096A1 (ru) | 4-оксо-3,4-дигидро-1,2,3-бензотриазины в качестве модуляторов gpr139 | |
| CY1121464T1 (el) | Στεροειδης ενωση για χρηση στην αντιμετωπιση της ηπατικης εγκεφαλοπαθειας | |
| EP3226899A4 (en) | Methods for treating dry eye disease by administering an il-6r antagonist | |
| MX2024015576A (es) | Tratamiento para migra?as | |
| MX383202B (es) | Sondas para la proyección de imagen de la proteína huntingtina. | |
| IL283414A (en) | Methods of treating conditions related to the s1p1 receptor | |
| AR106133A1 (es) | Métodos para el tratamiento de la epilepsia | |
| MX386798B (es) | Sondas para la proyección de imagen de la proteína huntingtina. | |
| LT3377094T (lt) | Susilpninto virulentiškumo bakterijos, skirtos piktybinių solidinių navikų gydymui | |
| EA201890764A1 (ru) | Селективные антагонисты nr2b | |
| MX392383B (es) | Metodos para tratar afecciones oculares. | |
| EA201790373A1 (ru) | Способы получения модуляторов toll-подобных рецепторов | |
| PH12016502235A1 (en) | Pharmaceutically acceptable salts of pirlindole enantiomers for use in medicine | |
| PL3423440T3 (pl) | Pochodna 5-metylo-6-fenylo-4,5-dihydro-2h-pirydazyn-3-onu do leczenia nowotworów mózgu | |
| LT3362056T (lt) | Aminotiolesterio junginiai arba jų farmaciniu požiūriu priimtinos druskos, skirti naudoti vėžio gydyme | |
| PL3664787T3 (pl) | Zastosowanie selektywnych agonistów receptora serotoninowego 5-HT1A do leczenia skutków ubocznych inhibitorów VMAT |